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Abstract
Individual differences in emotional processing are likely to contribute to vulnerability and resilience to
emotional disorders such as depression and anxiety. Genetic variation is known to contribute to these
differences but they remain incompletely understood. The serotonin transporter (5-HTTLPR) and a2B-
adrenergic autoreceptor (ADRA2B) insertion/deletion polymorphisms impact on two separate but inter-
acting monaminergic signalling mechanisms that have been implicated in both emotional processing and
emotional disorders. Recent studies suggest that the 5-HTTLPR s allele is associated with a negative
attentional bias and an increased risk of emotional disorders. However, such complex behavioural traits
are likely to exhibit polygenicity, including epistasis. This study examined the contribution of the
5-HTTLPR and ADRA2B insertion/deletion polymorphisms to attentional biases for aversive information
in 94 healthy male volunteers and found evidence of a significant epistatic effect (p<0.001). Specifically, in
the presence of the 5-HTTLPR s allele, the attentional bias for aversive information was attenuated by
possession of the ADRA2B deletion variant whereas in the absence of the s allele, the bias was enhanced.
These data identify a cognitive mechanism linking genotype-dependent serotonergic and noradrenergic
signalling that is likely to have implications for the development of cognitive markers for depression/
anxiety as well as therapeutic drug effects and personalized approaches to treatment.
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Introduction
Enhanced processing of emotionally salient in relation
to neutral information is normally considered to be an
adaptive process enabling threat detection and in-
creasing the probability of survival (Vuilleumier,
2005). However, there is considerable evidence that
biased processing of emotional information also plays
a role in the aetiology and maintenance of emotional
disorders such as depression and anxiety (Leppanen,
2006). The monoamine neurotransmitters (serotonin,
dopamine, noradrenaline) are known to play a
significant role in emotional processing and although
they are generally considered to act synergistically,
few studies have specifically investigated interactions
between these neurotransmitters.
Serotonin and noradrenaline are also heavily im-
plicated in the aetiology of emotional disorders and
the majority of therapeutic agents increase synaptic
levels of these neurotransmitters (Nutt, 2002). Despite
their use for over half a century, it remains unclear
how antidepressants exert their therapeutic effects.
More recently, evidence has emerged suggesting that
serotonergic and noradrenergic antidepressant drugs
may act by modifying emotional processing biases
(Harmer et al. 2009). Yet in spite of this increasing in-
sight, the fact that up to 50% of patients treated with
these medications fail to respond adequately remains
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a significant challenge in the management of these
disorders (Souery et al. 1999). Inter-individual dif-
ferences in responses to emotional stimuli may con-
tribute to differences in vulnerability to emotional
disorders as well as response to therapeutic agents
(Hamann & Canli, 2004). It is increasingly accepted
that genetic factors explain small but significant
amounts of this variability (Todd et al. 2011). Thus,
polymorphisms in genes involved in serotonergic and
noradrenergic signalling represent apposite candi-
dates for further investigation.
One of the genetic variants that have been most ex-
tensively investigated in relation to human emotional
processing and emotional disorders is the gene
encoding the serotonin transporter (5-HTT or
SLC6A4). An insertion/deletion polymorphism in the
promoter region of this gene (5-HTTLPR) results in two
common allelic variants : short (s) and long (l). The
former has been associated with reduced transporter
transcription, resulting in approximately 50% re-
duction in transporter availability in vitro and pre-
sumed increased synaptic serotonin availability (Heils
et al. 1996). More recently, an additional A/G single
nucleotide polymorphism (SNP) in the l allele (rs25531)
has been found to further influence transcriptional
activity. The G variant of the l allele is considered to
result in a reduction in transcriptional efficiency to a
level similar to that of the s allele (Hu et al. 2005;
Wendland et al. 2006). However, the frequency of this
G allele varies with ethnicity and it is relatively un-
common in white European ethnic groups (Hu et al.
2006). Early seminal studies linked the s allele to in-
creased neurotic personality traits (Lesch et al. 1996)
and an increased risk of depression in the context of
adverse life events (Caspi et al. 2003). Subsequent
studies examining the in-vivo effects of this genetic
variation on the phenotypic expression of 5-HTT in the
human brain have produced inconsistent results
(Praschak-Rieder et al. 2007; Reimold et al. 2007; van
Dyck et al. 2004; Willeit et al. 2000). However, consist-
ent with a number of previous studies, a relatively
large recent positron emission tomography (PET)
study in healthy volunteers found that polymorphic
variation in 5-HTTLPR did not alter expression of
5-HTT (Murthy et al. 2010). It has, however, been sug-
gested that this genetic variation instead contributes to
early neurodevelopmental changes that may impact
on brain structure and function in later life (Lesch &
Gutknecht, 2005). This would be consistent with the
further body of functional magnetic resonance
imaging (fMRI) literature that has more consistently
documented that s allele carriers demonstrate signifi-
cantly greater amygdala activation in response to
aversive, relative to neutral, stimuli in a variety of
emotional processing tasks (Bertolino et al. 2005; Canli
et al. 2005; Hariri et al. 2002, 2005 ; Heinz et al. 2004;
Pezawas et al. 2005; for ameta-analysis seeMunafo` et al.
2008). Yet, the behavioural implications of these neural
differences remained unclear. More recently a number
of studies have focused on ‘behavioural endo-
phenotypes’ such as selective attentional biases for
emotional information. To date, these studies have
demonstrated an association between the 5-HTTLPR s
allele and preferential attention to aversive stimuli
(Beevers et al. 2007, 2010, 2011 ; Fox et al. 2009; Osinsky
et al. 2008), although these reports have not been en-
tirely consistent (Caspi et al. 2010). One important
potential source of inconsistency and non-replication
in genetics studies of complex quantitative traits is the
issue of polygenicity, including biological epistasis
(Moore, 2008). However, none of these neuroimaging
or behavioural genetics studies has examined the ef-
fects of the other major neurotransmitter system im-
plicated in affective spectrum disorders and emotional
processing, i.e. the noradrenergic system.
Noradrenaline has an established role in modulat-
ing memory enhancement for emotionally arousing
information (McGaugh, 2004) and recent pharmaco-
logical challenge studies indicate that it is also in-
volved in modulating attentional biases for emotional
information in healthy human volunteers (De Martino
et al. 2008). However, the contribution of genetically
influenced differences in noradrenergic tone to inter-
individual differences in human emotional processing
has been largely unexplored. An insertion/deletion
polymorphism in the a2B-adrenergic (auto)receptor
gene (ADRA2B) has recently been found to contribute
to individual differences in emotionally influenced
memory processes. The deletion variant (Del301-303)
is associated with decreased agonist-promoted phos-
phorylation and receptor desensitization in vitro
(Small et al. 2001), presumed to be associated with in-
creased noradrenergic tone in vivo. In two seminal
studies, de Quervain and colleagues demonstrated
an association between this polymorphic variant, in-
creased amygdala reactivity and an increased memory
bias for emotional stimuli (de Quervain et al. 2007;
Rasch et al. 2009). However, the contribution of
ADRA2B to emotionally enhanced attentional pro-
cesses was not explored. It therefore remains possible
that the observed memory bias arises due to an atten-
tional advantage contributing to enhanced encoding of
emotional information (Todd et al. 2011). The purpose
of this study was therefore to test the hypothesis that
an increased attentional bias for emotionally arousing
information is associated with the deletion variants of
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ADRA2B and 5-HTTLPR and examine whether
these effects are subject to additive or non-additive
interactions.
Materials and methods
Participants
One hundred and seven healthy white British
male volunteers between the ages of 18 and 35 yr
(mean¡S.D.=24.0¡4.8) were recruited from the uni-
versity and local community. They had no lifetime
history of psychiatric or neurological disorder. Esti-
mates of verbal IQ were derived from the National
Adult Reading Test (NART; Nelson, 1982). The study
was approved by the local research ethics committee.
Following complete description of the study to the
participants, written informed consent was obtained.
Behavioural task
We used an emotional attention blink (AB) task based
on dual-target rapid serial visual presentation (RSVP)
methodology (Raymond et al. 1992). Identification of a
first target (T1) in a rapid stream of stimuli leads
to transient impairment in identification of a second
target (T2) – an effect, known as the attentional blink.
It has previously been used by us and others to dem-
onstrate a bias towards accurate detection of aversive
T2 targets compared to neutral (Anderson, 2005 ;
Anderson & Phelps, 2001 ; De Martino et al. 2008;
Gibbs et al. 2007; Keil & Ihssen, 2004). The task com-
prised 168 trials, each trial consisting of 13 white dis-
tracter words and 2 green target words (T1 and T2)
presented sequentially in the centre of a laptop
computer screen (see Fig. 1). T1 stimuli were all
neutral words averaging 4.8 letters in length. T2
words were derived from the Affective Norms for
English Words (Bradley & Lawson, 1999) and half
were aversive-arousing (mean valence and arousal
ratings of 2.5 and 7.0, respectively) and half were
neutral (mean valence and arousal ratings of 5.1 and
3.5, respectively). Aversive and neutral T2 stimuli did
not differ significantly in letter length (mean=5.1 vs.
4.8, respectively, p=0.21) or written word frequency
(mean=67.1 vs. 87.9, respectively, p=0.50) (Kucera &
Francis, 1967). Distracter items were 92 words of
longer length (mean letters=12.5) to facilitate masking
of the targets. Each item was presented for 100 ms and
was immediately followed by the subsequent item.
The lag between the T1 and T2 targets was varied to
contain one, three, or five intervening distracters (lag
2, lag 4 or lag 6) with corresponding stimulus onset
asynchronies (SOAs) of 200 ms, 400 ms or 600 ms.
Participants were instructed to ignore the words in
white (distracters) and identify the two green target
words (T1 and T2). Responses were made by partici-
pants writing down the two targets in any order
immediately after each trial on sheets that were sub-
sequently scored. Exact correct spelling was not
necessary for a correct response. Vowel and consonant
omissions, insertions or replacements were allowed
provided the word was recognizable and the spelling
was phonologically accurate.
Genotyping
DNA extraction and genotyping for the ADRA2B in-
sertion/deletion polymorphism was performed by
KBioscience, Hertfordshire, UK as previously reported
(Gibbs et al. 2010). For the 5-HTTLPR insertion/
deletion, polymerase chain reaction (PCR) was also
performed using KBioscience’s in-house SNP geno-
typing system (KASPar1) using fluorescently labelled
primers (pF1: Cy5.5-CCCAGCGTGCTCCAGAAAC;
pR: GGACCTGGGCAGTTGTGC). For technical
reasons, we were unable to complete further tri-allelic
genotyping of the A/G SNP (rs25531) in the
5-HTTLPR insertion allele.
Statistical analysis
Hardy–Weinberg equilibrium (HWE) of genetic data
was assessed by x2 analysis. Possible genotype-
dependent differences in demographic variables
between genotype groups were assessed in a multi-
variate analysis of variance (ANOVA) with age and IQ
as dependent variables and 5-HTTLPR and ADRA2B
genotypes as between-subjects factors. Genotype ef-
fects on T1 detection in the AB task were examined in
a univariate ANOVA with percent correct T1 report as
the dependent measure and 5-HTTLPR and ADRA2B
genotypes as the between-subjects factors. Affective
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Fig. 1. Schematic representation of attentional blink task.
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modulation of the AB effect was examined in a
repeated-measures ANOVA with the same between-
subjects factors, valence (aversive, neutral) and lag
(2, 4, 6) as within-subject factors and percent correct T2
report (contingent on the correct identification of T1)#
as the dependent measure. Significant interactions
were explored using post-hoc t tests. A Greenhouse–
Geisser correction was applied where sphericity as-
sumptions were violated.
Results
Genotypes
Of the 107 participants, ADRA2B genotypes were un-
available for two participants, 11 were homozygous
carriers of the ADRA2B deletion, 48 were hetero-
zygotes and 46 were non-carriers, consistent with
HWE (x2=0.09, p=0.77). Due to the small number of
homozygous carriers, they were combined with the
heterozygotes, giving two genotype groups of deletion
carriers (Del) and non-carriers (Ins) as previously done
by us and others (de Quervain et al. 2007; Gibbs et al.
2010). For 5-HTTLPR, 12 genotypes were unavailable,
35 were homozygous l/l, 41 were heterozygous s/l
and 19 were homozygous s/s, consistent with HWE
(x2=1.18, p=0.28). Given that the s allele is considered
to have a dominant effect (Lesch et al. 1996), partici-
pants were divided into two groups: homozygous or
heterozygous s allele carriers (S group) and non-
carriers (L group) consistent with previous studies
(Canli et al. 2005). Participants for whom genetic data
were not available for both polymorphisms were ex-
cluded from further analysis, leaving a total sample of
94. Demographic characteristics (age and IQ) are given
in Table 1. There were no genotype effects on these
variables.
Behavioural data
There was a significant main effect of valence on T2
detection accuracy [F(1, 90)=11.0, p=0.001], with
greater detection of aversive (92.7¡1.6%) compared to
neutral (81.2¡1.2%) words. T2 detection accuracy also
increased significantly [F(1.2, 109.4)=183.3, p<0.001]
as the temporal lag between the targets increased [lag
2=64.4¡22.2%; lag 4=83.8¡15.7%; lag 6=91.1¡
12.3%] and there was a significant lagrvalence inter-
action [F(2, 180=28.5, p<0.001] such that the
emotional attentional bias was most pronounced at lag
4 (9%) compared to lag 6 (3%) and lag 2 (x3%) where
it was absent. There were no main effects of the indi-
vidual genes ; however, there was a highly significant
ADRA2Br5-HTTLPRrvalence interaction [F(1, 90)=
15.0, p<0.001]. In order to clarify this interaction we
first conducted a separate repeated-measures ANOVA
in the 5-HTTLPR S and L groups with T2 detection as
the dependent variable, valence (aversive, neutral) as
the between-subjects variable and ADRA2B genotype
as the between-subjects variable. We found significant
ADRA2Brvalence interactions in both 5-HTLPR S
[F(1, 58)=8.2, p=0.006] and L [F(1, 32)=6.06, p=0.02]
groups. Post-hoc paired t tests demonstrated that in the
5-HTTLPR L group, there was a significant attentional
bias for aversive vs. neutral T2 words in ADRA2B
deletion carriers [t(20)=3.0, p=0.007, d=0.7] that was
absent in non-carriers [t(12)=x0.68, p=0.504].
Conversely, in the 5-HTTLPR S group, the significant
emotional attentional bias was absent in ADRA2B de-
letion carriers [t(29)=0.477, p=0.637] but present in
non-carriers [t(29)=4.9, p<0.001, d=1] (see Fig. 2).
There were no other significant main genotype effects
or interactions in relation to T1 or T2 detection.
Discussion
The purpose of this study was to examine the
effects of serotonergic (5-HTTLPR) and noradrenergic
(ADRA2B) genetic variants on attentional biases
for aversive stimuli using an attentional blink (AB)
Table 1. Demographic characteristics for 5-HTTLPR and ADRA2B genotypes
5-HTTLPR ADRA2B
S L F p Del Ins F p
Number of participants 34 60 – – 51 43 – –
Age, yr mean (S.D.) 23.9 (4.9) 23.9 (4.3) 0.02 (x) 0.88 (x) 24.7 (4.9) 23.0 (4.3) 1.18 (x) 0.31 (x)
IQ mean (S.D.) 105.9 (6.5) 104.4 (7.0) 2.28 (x) 0.14 (x) 106.7 (5.7) 104.7 (6.4) 3.01 (x) 0.06 (x)
# This is to guarantee that proper attention has been devoted to T1 to
ensure an AB effect.
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paradigm. To our knowledge, this is the first study to
examine the contribution of the ADRA2B insertion/
deletion polymorphism to individual differences in
emotional attentional biases and only the second study
to explore the genetic basis of the emotional AB effect
[Munafo` and colleagues previously found an associ-
ation between 5-HTTLPR genotype, smoking status
and detection of smoking-related stimuli in an AB task
(Munafo` et al. 2005)]. The significant novel finding
from this study is that the affective modulation of T2
detection is influenced by a non-additive (epistatic)
interaction between the ADRA2B and 5-HTTLPR in-
sertion/deletion polymorphisms.
Specifically, we found that a significant attentional
bias for aversive compared to neutral information was
present in individuals possessing at least one copy of
the short (s) allele of 5-HTTLPR, but only if they did
not carry the ADRA2B deletion. Conversely, the at-
tentional bias for emotional information was only
present in 5-HTTLPR long (l) allele homozygotes if
they were ADRA2B deletion carriers. This suggests
that in the presence of the 5-HTTLPR s allele which is a
putative risk allele for depressive and anxiety dis-
orders, the negative attentional bias is attenuated by
the ADRA2B deletion variant whereas in the absence
of the s allele, the bias is enhanced. Both of these effects
may be related to adaptive processes. For instance,
dependent on 5-HTTLPR genotype, the effect of the
ADRA2B deletion variant may be to either exert a
protective effect against affective spectrum disorders
or facilitate enhanced detection of threat, in both cases
contributing to increased probability of survival.
Behavioural genetics implications
We did not find a main effect of 5-HTTLPR on
emotional attention as a number of previous studies
have done (Beevers et al. 2007; Fox et al. 2009; Munafo`
et al. 2005; Osinsky et al. 2008). However, with the
exception of Munafo` et al. (2005), all of these studies
used a variation of the dot probe task to evaluate
emotional biases in selective attention, rather than the
AB task. Although both of these tasks evaluate selec-
tive attention when cognitive resources are limited,
the latter measures deployment of attention resources
under temporal constrains while the former typically
utilizes spatial limitations. Notably, Munafo` et al.
(2005) also used an alternate variant of the AB task that
indexes attention by establishing whether the detec-
tion of a neutral T2 target is impaired when preceded
by an emotionally salient or neutral T1 target. It is
possible that these task-related differences may ac-
count for the difference in findings. Yet the studies
reporting positive associations using the dot probe
task are not without inconsistencies. For example
some have linked the s allele to biases towards aversive
stimuli (Beevers et al. 2007; Osinsky et al. 2008) while
others suggest that the l allele results in biases away
from negative stimuli (Fox et al. 2009; Kwang et al.
2010). Other discrepancies include 5-HTTLPR associ-
ations found only with long (Osinsky et al. 2008) or
short (Beevers et al. 2007) stimulus presentation dur-
ations. In spite of using shared dot probe method-
ology, there are still significant differences between
these studies in terms of subjects (healthy volunteers
vs. psychiatric patients ; men vs. women), stimuli
(words vs. spiders vs. pictorial scenes) and duration of
stimulus presentation (<500 ms vs. >500 ms). These
differences highlight the need for task consistency in
future studies in order to facilitate replication (NCI-
NHGRI Working Group on Replication in Association
Studies, 2007).
The effect of the ADRA2B insertion/deletion
polymorphism on attentional biases for emotional
information has not been previously investigated.
However, it has been suggested that it might contrib-
ute to the emotional memory bias observed in
ADRA2B deletion carriers (Todd & Anderson, 2009).
We did not find any main effect of ADRA2B on
emotional attention in this study suggesting that the
ADRA2B deletion variant does not independently bias
attention towards emotional stimuli but may interact
with other monaminergic gene systems to contribute
to such bias.
Behavioural pharmacogenetics implications
A number of studies have begun to examine possible
interactions between 5-HTTLPR polymorphisms,
emotional attentional biases and the effects of sero-
tonergic manipulation by acute tryptophan depletion
(ATD) but have thus far failed to produce consistent
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Fig. 2. Accuracy (percent correct) of T2 detection in
5-HTTLPR and ADRA2B groups.
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findings (Firk & Markus, 2009 ; Markus & De Raedt,
2011 ; Markus & Firk, 2009 ; Roiser et al. 2007). This
may in part be due to the fact that ATD in healthy
volunteers, independent of genotype, has not pro-
duced entirely consistent effects on emotional pro-
cessing (Hayward et al. 2005; Murphy et al. 2002;
Rubinsztein et al. 2001). No studies have as yet exam-
ined the possible contribution of genetic variation to
the effects of serotonergic and noradrenergic drugs on
emotional attention. However, a number of pharma-
cological studies have examined the effects of sero-
tonergic and noradrenergic drugs on emotional
processing in healthy subjects (Arce et al. 2008; Arnone
et al. 2009; Bru¨hl et al. 2009; Harmer et al. 2008, 2003,
2004 ; Murphy et al. 2009a ; Norbury et al. 2007;
Rawlings et al. 2010). This work may be relevant to
understanding the present findings; however, it is
difficult to make direct comparisons between geneti-
cally and pharmacologically mediated effects on
emotional processing as highlighted in the Clinical
implications subsection below. Additionally, only
three of these studies have specifically examined at-
tentional biases and these have produced relatively
inconsistent findings (Browning et al. 2007; De
Martino et al. 2008; Murphy et al. 2009b).
Using a dot probe task, Browning et al. (2007) found
that the administration of a single dose of the selective
serotonin reuptake inhibitor (SSRI) antidepressant
citalopram to healthy volunteers resulted in an atten-
tional bias towards positive words (Browning et al.
2007). This is consistent with some of the behavioural
findings in relation to the 5-HTTLPR l allele described
above. On an AB task, De Martino and colleagues
found that a single dose of the noradrenaline reuptake
inhibitor (NRI) reboxetine boosted detection of
emotionally arousing compared to neutral words in
healthy volunteers (De Martino et al. 2008). Also on a
dot probe task in healthy volunteers, Murphy et al.
(2009a, b) found that repeated citalopram adminis-
tration reduced the attentional bias towards emotional
faces, independently of valence, while reboxetine had
no effect (Murphy et al. 2009b). These apparently con-
flicting findings could again be related to differences
in methodology (dot probe vs. AB, words vs. faces,
single vs. repeated dosing). In fact, there is evidence
from both animal and human studies that acute and
chronic citalopram administration may differentially
influence emotional processing such that acute
doses result in an initial increase in the processing
of negative information that is attenuated with re-
peated dosing (Burghardt et al. 2004; Harmer et al.
2003, 2004). However genotype-dependent drug
effects may also contribute to these differences. For
example, pharmacological enhancement or attenu-
ation of emotional attentional biases may be less
prominent in individuals with genotype-related
emotional processing biases or in whom such biases
are absent, respectively. If emotional attentional bias is
to function as an effective cognitive marker, future
pharmacological challenge studies will also need to
consider the contribution of genetic variations in the
neurotransmitter systems under investigation. There
is also an increasing need to evaluate the effects of
genetic epistasis between these systems as this may
have important clinical implications for the pharma-
cogenetics of depression and anxiety.
Clinical implications
That such biological epistasis exists between sero-
tonergic and noradrenergic genes, is consistent with
the fact that these neurotransmitter systems are inti-
mately connected in the central nervous system
(de Boer, 1995). Noradrenergic neurotransmission is
modulated by presynaptic inhibitory a2-adrenergic
(auto)receptors and their blockade increases synaptic
levels of noradrenaline.However, there is evidence that
serotonergic neurotransmission is also modulated by
presynaptic a2-adrenergic (hetero)receptors (Clement
et al. 1992; De Boer et al. 1994; Mongeau et al. 1993). Yet
precisely how these systems may interact to produce
the intermediate phenotypes and the clinical disorders
themselves remains unclear. The fact that the majority
of drugs used to treat affective spectrum disorders act
by inhibiting the serotonin transporter seems at odds
with the fact that individuals with genetically influ-
enced reductions in serotonin transporter function
have greater risks of developing these disorders, as
well as poorer treatment response rates (Lesch &
Gutknecht, 2005). This ostensible contradiction is in-
creasingly understood in terms of the complex auto-
regulatory processes governing serotonergic function
(Routledge & Middlemiss, 1996) and the potentially
deleterious neurodevelopmental effects of excessive
intra-synaptic accumulation of serotonin (Lesch &
Gutknecht, 2005). Via its intimate relationship with
serotonergic signalling, the ADRA2B polymorphism
may also exert its epistatic effects via these auto-
regulatory and neurodevelopmental mechanisms.
While this hypothesis warrants further investi-
gation, the biological epistasis suggested in the present
study may have important implications for individual
responses to serotonergic and noradrenergic anti-
depressant drugs. Most pharmacogenetics studies
in depression have focused on variations in 5-HTT
(Schosser & Kasper, 2009 ; Serretti et al. 2007).
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However, two large recent projects (STAR*D and
GENDEP) have found associations between anti-
depressant response and a number of candidate genes
involved in both serotonin and noradrenaline signal-
ling (Hu et al. 2007; McMahon et al. 2006; Paddock et al.
2007; Uher et al. 2009), although none of these studies
included the ADRA2B polymorphism. The GENDEP
project did examine a polymorphism in the related
ADRA2A gene encoding a2A-adrenoceptor subtype
but failed to find any significant effect despite a
previously reported association with the response
to the serotonin-noradrenaline reuptake inhibitor
milnacipran (Wakeno et al. 2008). Of note, neither of
the two antidepressants evaluated in GENDEP was a
molecular target of the a2-adrenoceptor group.
Thus, the role of polymorphic variation in a2-
adrenergic receptors (and their interaction with sero-
tonergic targets) in the therapeutic response of
patients with affective spectrum disorders warrants
further investigation.
Study limitations
The purpose of this study was to investigate epistatic
effects of serotonergic and noradrenergic genes on
emotional attentional biases. However, the fact that we
measured only two polymorphisms out of a number
that might contribute to the behavioural effect of in-
terest represents a limitation to this study. Most sig-
nificantly, we were unable to genotype the additional
rs25531 SNP in the long allele of the 5-HTT gene.
However, given that the prevalence of the LG allele
is low (y10%), this is unlikely to have significantly
biased our findings. A further limitation is that al-
though the overall sample size was reasonable, there
were relatively few individuals in some genotype
combinations. This is a particular difficulty inherent in
measuring epistatic gene effects (Moore, 2008). Future
studies will need to use large sample sizes and evolv-
ing methodologies to effectively evaluate the likely
effects on emotional processing of multiple gene in-
teractions (Cordell, 2009). The final limitation is that
we only used aversive stimuli and male volunteers.
While the latter eliminated possible biases associated
with gender differences in emotional processing, it
limits the generalizability of our findings. It is there-
fore unclear whether the observed biases are valence
and/or gender specific. Additionally the aversive
stimuli used included range of negative emotions
(disgust, fear, sadness) rather than specifically dys-
phoric or threat-related emotions. It is therefore un-
clear how these processing biases might map onto
those considered to relate to depression and anxiety
disorders. Further studies with larger sample sizes
including men and women will be required to repli-
cate and extend our findings.
Conclusions
In spite of these limitations, this study begins to con-
tribute to the understanding of multiple gene effects
and interactions in an established cognitive marker for
affective spectrum disorders – the negative attentional
bias. It further underlines the potential utility of
adopting the ‘endophenotype’ approach in pharma-
cogenetics studies, i.e. examining the genetic factors
underlying not only the clinical response but also re-
sponses in cognitive and neural markers. One signifi-
cant challenge for such studies will be to delineate
the interaction between potential neurodevelopmental
effects of genetic polymorphisms influencing brain
neurotransmitter systems and the acute/sub-acute
effects of drug administration. Knockout and trans-
genic mouse models are likely to be useful in
appreciating the dynamics of the behavioural–
psychopharmacogenetic–neurodevelopmental inter-
face.
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